According to Herrmann and coworkers, CD34+CD38− CML patient cells in the chronic phase are reported to have a roughly 10-fold higher expression of CD33 compared to normal CD34+CD38− stem cells by flow cytometric analysis, even though CD33 remains comparable at the transcript level [42]. The gene discussed is CD33; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.